scholarly journals Detection of Human Cytomegalovirus Proteins in Paraffin-Embedded Breast Cancer Tissue Specimens—A Novel, Automated Immunohistochemical Staining Protocol

2021 ◽  
Vol 9 (5) ◽  
pp. 1059
Author(s):  
Joel Touma ◽  
Yan Liu ◽  
Afsar Rahbar ◽  
Mattia Russel Pantalone ◽  
Nerea Martin Almazan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Cytomegalovirus ◽  
Immunohistochemical Staining ◽  
University Hospital ◽  
Cancer Tissue ◽  
Clinical Value ◽  
Highly Sensitive ◽  
Late Antigen ◽  
Staining Protocol ◽  
Tissue Specimens

Emerging evidence supports a significant association between human cytomegalovirus (HCMV) and human malignancies, suggesting HCMV as a human oncomodulatory virus. HCMV gene products are found in >90% of breast cancer tumors and seem to be correlated with more aggressive disease. The definitive diagnosis of HCMV relies on identification of virus inclusions and/or viral proteins by different techniques including immunohistochemical staining. In order to reduce biases and improve clinical value of HCMV diagnostics in oncological pathology, automation of the procedure is needed and this was the purpose of this study. Tumor specimens from 115 patients treated for primary breast cancer at Akershus University Hospital in Norway were available for the validation of the staining method in this retrospective study. We demonstrate that our method is highly sensitive and delivers excellent reproducibility for staining of HCMV late antigen (LA), which makes this method useful for future routine diagnostics and scientific applications.

Comparison of the Results of PCR Analysis of Gene Expression in Breast Cancer Tissue Specimens Stabilized in Formalin and RNAlater

2014 ◽  
Vol 156 (4) ◽  
pp. 486-490 ◽  
Author(s):  
N. A. Khaustova ◽  
D. S. Makeeva ◽  
O. V. Kondrashina ◽  
N. N. Fedotov ◽  
I. N. Nechaev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Breast Cancer Tissue ◽  
Pcr Analysis ◽  
Cancer Tissue ◽  
Tissue Specimens ◽  
Comparison Of The Results

scholarly journals Scale-Specific Multifractal Medical Image Analysis

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Boris Braverman ◽  
Mauro Tambasco
Keyword(s):  
Breast Cancer ◽  
Fractal Analysis ◽  
Large Scale ◽  
Medical Images ◽  
Medical Image Analysis ◽  
Cancer Tissue ◽  
Clinical Value ◽  
Box Counting ◽  
Dependent Parameter ◽  
Single Number

Fractal geometry has been applied widely in the analysis of medical images to characterize the irregular complex tissue structures that do not lend themselves to straightforward analysis with traditional Euclidean geometry. In this study, we treat the nonfractal behaviour of medical images over large-scale ranges by considering their box-counting fractal dimension as a scale-dependent parameter rather than a single number. We describe this approach in the context of the more generalized Rényi entropy, in which we can also compute the information and correlation dimensions of images. In addition, we describe and validate a computational improvement to box-counting fractal analysis. This improvement is based on integral images, which allows the speedup of any box-counting or similar fractal analysis algorithm, including estimation of scale-dependent dimensions. Finally, we applied our technique to images of invasive breast cancer tissue from 157 patients to show a relationship between the fractal analysis of these images over certain scale ranges and pathologic tumour grade (a standard prognosticator for breast cancer). Our approach is general and can be applied to any medical imaging application in which the complexity of pathological image structures may have clinical value.

Immunohistochemical Staining of Metastatic Ductal Carcinomas of the Breast by Monoclonal Antibodies used in Imaging and Therapy: A Comparative Study

1995 ◽  
Vol 10 (3) ◽  
pp. 129-135 ◽  
Author(s):  
L.P. Howell ◽  
S.J. Denardo ◽  
N.B. Levy ◽  
J. Lund ◽  
G.L. Denardo
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibodies ◽  
Immunohistochemical Staining ◽  
Tumor Tissue ◽  
Ductal Carcinoma ◽  
Immunoperoxidase Staining ◽  
Cancer Tissue ◽  
Carcinoma Of The Breast ◽  
Normal Tissues ◽  
Metastatic Lesions

Five monoclonal antibodies (MoAbs) (L6, 170H.82, 155, BrE-3 and BR96), most of which have been previously shown to target breast cancer and not normal tissues by immunoscintigraphic imaging, were evaluated for their frequency and pattern of immunohistochemical staining in 67 to 116 metastatic lesions from patients with ductal carcinoma of the breast. Immunoperoxidase staining in 75% or more of the cells occurred in 56/116 (48%) for L6, 44189 (49%) for Br, -96, 58/102 (57%) for 155, 62/99 (84%) for 170H.82, and 65.67 (97%) for BrE-3. With the first three MoAbs, an additional 6-10% of the tumors showed staining in 50-75% of tumor cells. These results illustrate that most patients with metastatic ductal carcinoma have cancer tissue in which a high percent of cells will react to several of these selected MoAbs that target different epitopes. The high expression of the MoAb targets throughout the tumor tissue makes these antibodies potential candidates to carry immunologically directed radioimmunotherapy and is an aid in selecting patients for treatment..

Quantitative Assessment of HER-2/Neu Protein Concentration in Breast Cancer by Enzyme-Linked Immunosorbent Assay

2003 ◽  
Vol 18 (1) ◽  
pp. 13-20 ◽  
Author(s):  
V. Müller ◽  
C. Thomssen ◽  
C. Karakas ◽  
I. Eustermann ◽  
J. Ramirez Porras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Immunosorbent Assay ◽  
Immunohistochemical Staining ◽  
Protein Concentration ◽  
Tumor Tissue ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cancer Tissue ◽  
Tissue Extracts ◽  
Her 2

Purpose The HER-2/neu protein (p185) has become a promising target for antibody therapy in breast cancer. We tested the feasibility of a quantitative approach for HER-2/neu testing based on the analysis of tumor tissue extracts by an enzyme-linked immunosorbent assay (ELISA). Experimental design Tumor tissue extracts of primary human breast cancers (n=124) were prepared using a triton-based buffer. HER-2/neu concentration was quantified by ELISA. Paraffin-embedded tissue sections of the same tumors were analyzed by immunohistochemical staining applying the monoclonal HER-2/neu antibody TAB 250 (n=124) and by chromogenic in situ hybridization (CISH) (n=73). Results Concentrations of p185 in tissue extracts determined by ELISA varied from 1 to 927 ng per mg protein with a median of 25 ng/mg protein, whereas normal breast tissue showed values from 0.4 to 5.5 ng/mg with a median of 2.2 ng/mg (p<0.0001, Mann-Whitney U test). A significant correlation between p185 concentration and immunohistochemical staining was observed (p<0.0001, Kruskal-Wallis test). In addition, p185 concentration measured by ELISA was correlated with the degree of HER-2/neu gene amplification determined by CISH. HER-2/neu-amplified tumors had significantly higher p185 concentrations (median value 181 ng/mg protein) than non-amplified tumors (median value 20 ng/mg; p<0.0001, Mann-Whitney U test). Conclusions ELISA-based measurement of HER-2/neu protein concentration in breast cancer tissue extracts is feasible and provides quantitative results for p185 protein concentrations that correlate closely with HER-2/neu immunoscore and gene amplification.

Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 7561-7561 ◽  
Author(s):  
Karen Wakamiya ◽  
Marsha Hudson ◽  
Hayley Finkelstein ◽  
Mai Nguyen ◽  
Sara Alvarez ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cancer Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hematologic Malignancies ◽  
Staining Intensity ◽  
Cancer Tissue ◽  
Cd38 Expression ◽  
Staining Protocol ◽  
Tissue Specimens

7561 Background: CD38 is a type II transmembrane glycoprotein expressed on normal lymphoid and myeloid cells and can be highly expressed in hematologic malignancies. An IHC prototype assay was developed to detect CD38 expression in formalin-fixed, paraffin-embedded (FFPE) tissue specimens from three relapsed or refractory non-Hodgkin’s lymphoma (NHL) subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL) for selection of patients for treatment with daratumumab in a Phase 2 clinical trial (NCT02413489). Methods: This assay is based on EnVision FLEX IHC technology using CD38, clone DAK-CD38, primary antibody that has been developed and manufactured by Agilent Technologies. The assay staining protocol was developed for Dako PT Link and Autostainer Link 48. Specificity of DAK-CD38 staining was demonstrated by Western blot analysis of cancer cell lysates, as well as IHC on both normal and cancer tissue. Assay precision and robustness were evaluated using commercially procured FFPE DLBCL, FL and MCL specimens. Results: CD38 IHC DAK-CD38 detected a broad range of CD38 expression in DLBCL, FL, and MCL specimens. FFPE specimens derived from cancer cell lines exhibited a range of IHC staining intensity and confirmed the reported expression of CD38 in the scientific literature. All precision and robustness results met acceptance criteria for both IHC intensity and percent positive cells staining. Conclusions: Our studies demonstrate that the Dako CD38 IHC DAK-CD38 assay is sensitive, specific, precise, and robust for the detection of CD38 expression in DLBCL, FL and MCL. This assay may also have the potential to be used for the detection of CD38 in additional tumor types.

scholarly journals Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Xiao-Fang Dong ◽  
Yan Wang ◽  
Bi-Fei Huang ◽  
Gui-Nv Hu ◽  
Jun-Kang Shao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Multiple Logistic Regression Analysis ◽  
Tumor Grade ◽  
Molecular Classification ◽  
Cancer Tissue ◽  
Luminal A ◽  
Luminal B ◽  
Patient Prognosis ◽  
Tissue Specimens

It is unclear whether the methyltransferase-like 14 (METTL14) protein promotes or suppresses cancer growth. We examined the association between METTL14 expression, cancer progression, and patient prognosis in a total of 398 breast cancer tissue specimens. Significantly fewer cancer tissue specimens compared with normal breast tissue expressed high levels of METTL14 (52.8% vs. 75.0%). METTL14 expression was negatively associated with tumor grade and positively associated with patient age, estrogen, and progesterone receptor status. High METTL14 expression was more common in luminal A and luminal B tissue (75.9% and 60.8%, respectively), compared with human epidermal growth factor receptor 2- (HER2-) enriched and triple-negative breast cancer (TNBC) samples (38.2% and 18.6%, respectively). In multiple logistic regression analysis, independent predictors of METTL14 expression in breast cancer included higher tumor grade ( odds   ratio   OR = 0.494 , 95% confidence interval (CI): 0.289–0.844; P = 0.010 ), TNBC subtype ( OR = 0.109 , 95% CI: 0.054–0.222; P < 0.001 ), and HER2-enriched subtype ( OR = 0.298 , 95% CI: 0.156–0.567; P < 0.001 ). No clear relationship was observed between patient prognosis and METTL14 expression. It appears that downregulated METTL14 expression in breast cancer is associated with tumor grade and molecular classification.

Sign in / Sign up

Export Citation Format

Share Document